• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

用于治疗急性髓系白血病的图司替尼的临床前开发

Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia.

作者信息

Sonowal Himangshu, Rice William G, Bejar Raphael, Byun Joo-Yun, Jung Seung Hyun, Sinha Ranjeet, Howell Stephen B

机构信息

Department of Medicine and the Moores Cancer Center, University of California, San Diego, San Diego, California.

Aptose Biosciences, Inc., San Diego, California.

出版信息

Cancer Res Commun. 2025 Jan 1;5(1):74-83. doi: 10.1158/2767-9764.CRC-24-0258.

DOI:10.1158/2767-9764.CRC-24-0258
PMID:39665627
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11725774/
Abstract

This article reports preclinical development of TUS, an oral kinase inhibitor currently in clinical development for treatment of AML. The article covers the studies of TUS activities on cellular targets and the nonclinical studies that supported the advancement of TUS to a phase I/II trial of TUS/VEN in refractory AML and a phase I/II trial of TUS/VEN/5-azacytidine in newly diagnosed patients with AML (NCT03850574).

摘要

本文报道了TUS的临床前开发情况，TUS是一种口服激酶抑制剂，目前正处于治疗急性髓系白血病（AML）的临床开发阶段。本文涵盖了TUS对细胞靶点活性的研究以及支持TUS推进至难治性AML的TUS/VEN I/II期试验和新诊断AML患者的TUS/VEN/5-氮杂胞苷I/II期试验（NCT03850574）的非临床研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31e4/11725774/84bac25f29ce/crc-24-0258_f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31e4/11725774/3d07c4ef51b8/crc-24-0258_f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31e4/11725774/84bac25f29ce/crc-24-0258_f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31e4/11725774/3d07c4ef51b8/crc-24-0258_f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31e4/11725774/84bac25f29ce/crc-24-0258_f5.jpg

相似文献

1
Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia.用于治疗急性髓系白血病的图司替尼的临床前开发
Cancer Res Commun. 2025 Jan 1;5(1):74-83. doi: 10.1158/2767-9764.CRC-24-0258.
2
Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax results in promising antileukemic activity against FLT3-ITD AML.新型 FLT3 和 MERTK 双重抑制剂 MRX-2843 与 venetoclax 联合应用对 FLT3-ITD AML 具有有前景的抗白血病活性。
Leuk Res. 2024 Sep;144:107547. doi: 10.1016/j.leukres.2024.107547. Epub 2024 Jun 24.
3
Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia.新型酪氨酸激酶抑制剂 ArQule 531 治疗急性髓系白血病的临床前疗效。
J Hematol Oncol. 2020 Jan 28;13(1):8. doi: 10.1186/s13045-019-0821-7.
4
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.突变型FLT3：急性髓性白血病中索拉非尼的直接作用靶点。
J Natl Cancer Inst. 2008 Feb 6;100(3):184-98. doi: 10.1093/jnci/djm328. Epub 2008 Jan 29.
5
Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine.联合 venetoclax 和 8-氯腺苷靶向急性髓系白血病原始细胞的代谢脆弱性。
J Hematol Oncol. 2021 Apr 26;14(1):70. doi: 10.1186/s13045-021-01076-4.
6
[Efficacy of Venetoclax Plus Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia Patients with Mutation].维奈托克联合阿扎胞苷治疗复发/难治性急性髓系白血病患者伴突变的疗效
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023 Oct;31(5):1333-1339. doi: 10.19746/j.cnki.issn.1009-2137.2023.05.013.
7
(R)-WAC-224, a new anticancer quinolone, combined with venetoclax and azacitidine overcomes venetoclax-resistant AML through MCL-1 downregulation.(R)-WAC-224，一种新型抗癌喹诺酮类药物，与维奈克拉和阿扎胞苷联合使用，通过下调MCL-1克服维奈克拉耐药的急性髓系白血病。
Sci Rep. 2025 May 8;15(1):16018. doi: 10.1038/s41598-025-98534-7.
8
Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.单中心儿科应用维奈托克联合阿扎胞苷治疗骨髓增生异常综合征和急性髓系白血病的经验。
Pediatr Blood Cancer. 2020 Oct;67(10):e28398. doi: 10.1002/pbc.28398. Epub 2020 Jul 31.
9
Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.初诊老年或复发/难治性成人急性髓系白血病患者使用地西他滨联合米哚妥林（PKC412）的临床前和 I 期研究结果。
Pharmacotherapy. 2013 Dec;33(12):1341-52. doi: 10.1002/phar.1316. Epub 2013 Jun 24.
10
Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia.联合使用 STAT5 抑制剂 AC-4-130 和 MCL1 抑制剂 S63845 治疗 FLT3 突变或 TET2 突变急性髓系白血病的理由。
Int J Mol Sci. 2021 Jul 28;22(15):8092. doi: 10.3390/ijms22158092.

引用本文的文献

1
A Phage-Based Approach to Identify Antivirulence Inhibitors of Bacterial Type IV Pili.一种基于噬菌体的方法来鉴定细菌IV型菌毛的抗毒力抑制剂。
Microb Biotechnol. 2025 Jan;18(1):e70081. doi: 10.1111/1751-7915.70081.

本文引用的文献

1
Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation.PI3K 激酶抑制剂通过激活 GSK-3β和泛素蛋白酶体途径降解 c-Myc 和 Mcl-1 增强 FLT3-ITD 急性髓系白血病中吉特替尼的细胞毒性。
Cancer Res Commun. 2024 Feb 16;4(2):431-445. doi: 10.1158/2767-9764.CRC-23-0379.
2
FLT3 targeting in the modern era: from clonal selection to combination therapies.现代时代的 FLT3 靶向治疗：从克隆选择到联合治疗。
Int J Hematol. 2024 Nov;120(5):528-540. doi: 10.1007/s12185-023-03681-0. Epub 2023 Dec 19.
3
Signaling pathways governing the behaviors of leukemia stem cells.
调控白血病干细胞行为的信号通路。
Genes Dis. 2023 Mar 23;11(2):830-846. doi: 10.1016/j.gendis.2023.01.008. eCollection 2024 Mar.
4
The GSK3β/Mcl-1 axis is regulated by both FLT3-ITD and Axl and determines the apoptosis induction abilities of FLT3-ITD inhibitors.GSK3β/Mcl-1轴受FLT3-ITD和Axl两者调控，并决定FLT3-ITD抑制剂的凋亡诱导能力。
Cell Death Discov. 2023 Feb 4;9(1):44. doi: 10.1038/s41420-023-01317-0.
5
Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells.急性髓系白血病干细胞的耐药机制
Front Oncol. 2022 Jul 5;12:896426. doi: 10.3389/fonc.2022.896426. eCollection 2022.
6
Venetoclax Plus Gilteritinib for -Mutated Relapsed/Refractory Acute Myeloid Leukemia.维奈克拉联合吉特替尼治疗 - 突变的复发/难治性急性髓系白血病。
J Clin Oncol. 2022 Dec 10;40(35):4048-4059. doi: 10.1200/JCO.22.00602. Epub 2022 Jul 18.
7
Venetoclax resistance: mechanistic insights and future strategies.维奈托克耐药性：机制见解与未来策略
Cancer Drug Resist. 2022 May 6;5(2):380-400. doi: 10.20517/cdr.2021.125. eCollection 2022.
8
Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib.ADMIRAL 研究中 gilteritinib 治疗复发/难治性 AML 伴 FLT3 突变患者的分子特征。
Blood Adv. 2022 Apr 12;6(7):2144-2155. doi: 10.1182/bloodadvances.2021006489.
9
Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes.维奈托克联合疗法治疗急性髓系白血病和骨髓增生异常综合征。
Curr Opin Hematol. 2022 Mar 1;29(2):63-73. doi: 10.1097/MOH.0000000000000698.
10
Microenvironment and drug resistance in acute myeloid leukemia: Do we know enough?急性髓系白血病的微环境与耐药性：我们了解得足够多吗？
Int J Cancer. 2022 May 1;150(9):1401-1411. doi: 10.1002/ijc.33908. Epub 2021 Dec 24.